Efficacy and safety of teneligliptin, a dipeptidyl peptidase‐4 inhibitor, combined with metformin in
            K
            orean patients with type 2 diabetes mellitus: a 16‐week, randomized, double‐blind, placebo‐controlled phase
            III
            trial

M. K. Kim; E.‐J. Rhee; K. A. Han; A. C. Woo; M.‐K. Lee; B. J. Ku; C. H. Chung; K.‐A. Kim; H. W. Lee; I. B. Park; J. Y. Park; H. C. Chul Jang; K. S. Park; W. I. Jang; B. Y. Cha

doi:10.1111/dom.12424

Efficacy and safety of teneligliptin, a dipeptidyl peptidase‐4 inhibitor, combined with metformin in K orean patients with type 2 diabetes mellitus: a 16‐week, randomized, double‐blind, placebo‐controlled phase III trial

Diabetes Obesity and Metabolism ◽

10.1111/dom.12424 ◽

2015 ◽

Vol 17 (3) ◽

pp. 309-312 ◽

Cited By ~ 22

Author(s):

M. K. Kim ◽

E.‐J. Rhee ◽

K. A. Han ◽

A. C. Woo ◽

M.‐K. Lee ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Dipeptidyl Peptidase 4 ◽

Dipeptidyl Peptidase 4 Inhibitor

Download Full-text

Efficacy and safety of teneligliptin, a novel dipeptidyl peptidase-4 inhibitor, in Korean patients with type 2 diabetes mellitus: a 24-week multicentre, randomized, double-blind, placebo-controlled phase III trial

Diabetes Obesity and Metabolism ◽

10.1111/dom.12631 ◽

2016 ◽

Vol 18 (5) ◽

pp. 528-532 ◽

Cited By ~ 12

Author(s):

S. Hong ◽

C.-Y. Park ◽

K. A. Han ◽

C. H. Chung ◽

B. J. Ku ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Dipeptidyl Peptidase 4 ◽

Dipeptidyl Peptidase 4 Inhibitor

Download Full-text

Efficacy and safety of gemigliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24-week, multicentre, randomized, double-blind, placebo-

Diabetes Obesity and Metabolism ◽

10.1111/dom.12866 ◽

2017 ◽

Vol 19 (5) ◽

pp. 635-643 ◽

Cited By ~ 6

Author(s):

Chang Ho Ahn ◽

Kyung Ah Han ◽

Jae Myung Yu ◽

Joo Young Nam ◽

Kyu Jeung Ahn ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Combination Treatment ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Dipeptidyl Peptidase 4 ◽

Dipeptidyl Peptidase 4 Inhibitor

Download Full-text

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study

Current Medical Research and Opinion ◽

10.1185/03007990903156111 ◽

2009 ◽

Vol 25 (10) ◽

pp. 2361-2371 ◽

Cited By ~ 97

Author(s):

Richard E. Pratley ◽

Jane E.-B. Reusch ◽

Penny R. Fleck ◽

Craig A. Wilson ◽

Qais Mekki ◽

...

Keyword(s):

Type 2 Diabetes ◽

Dipeptidyl Peptidase ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Dipeptidyl Peptidase 4 ◽

Dipeptidyl Peptidase 4 Inhibitor

Download Full-text

Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Alogliptin in Patients With Type 2 Diabetes and Inadequate Glycemic Control: A randomized, double-blind, placebo-controlled study

Diabetes Care ◽

10.2337/dc08-1035 ◽

2008 ◽

Vol 31 (12) ◽

pp. 2315-2317 ◽

Cited By ~ 159

Author(s):

R. A. DeFronzo ◽

P. R. Fleck ◽

C. A. Wilson ◽

Q. Mekki ◽

Keyword(s):

Type 2 Diabetes ◽

Glycemic Control ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Dipeptidyl Peptidase 4 ◽

Dipeptidyl Peptidase 4 Inhibitor ◽

Inadequate Glycemic Control

Download Full-text

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study

Clinical Therapeutics ◽

10.1016/j.clinthera.2006.10.007 ◽

2006 ◽

Vol 28 (10) ◽

pp. 1556-1568 ◽

Cited By ~ 354

Author(s):

Julio Rosenstock ◽

Ronald Brazg ◽

Paula J. Andryuk ◽

Kaifeng Lu ◽

Peter Stein

Keyword(s):

Type 2 Diabetes ◽

Dipeptidyl Peptidase ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Dipeptidyl Peptidase 4 ◽

Parallel Group Study ◽

Dipeptidyl Peptidase 4 Inhibitor ◽

Parallel Group

Download Full-text

Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study

International Journal of Clinical Practice ◽

10.1111/j.1742-1241.2008.01933.x ◽

2009 ◽

Vol 63 (1) ◽

pp. 46-55 ◽

Cited By ~ 149

Author(s):

M. A. Nauck ◽

G. C. Ellis ◽

P. R. Fleck ◽

C. A. Wilson ◽

Q. Mekki ◽

...

Keyword(s):

Type 2 Diabetes ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Metformin Therapy ◽

Dipeptidyl Peptidase 4 ◽

Metformin Monotherapy ◽

Dipeptidyl Peptidase 4 Inhibitor

Download Full-text

Efficacy and safety of fasiglifam ( TAK ‐875), a G protein‐coupled receptor 40 agonist, in J apanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double‐blind, placebo‐controlled, phase III trial

Diabetes Obesity and Metabolism ◽

10.1111/dom.12467 ◽

2015 ◽

Vol 17 (7) ◽

pp. 675-681 ◽

Cited By ~ 78

Author(s):

K. Kaku ◽

K. Enya ◽

R. Nakaya ◽

T. Ohira ◽

R. Matsuno

Keyword(s):

Type 2 Diabetes ◽

G Protein ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Diet And Exercise ◽

G Protein Coupled

Download Full-text

Phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of teneligliptin monotherapy in Chinese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise

Journal of Diabetes Investigation ◽

10.1111/jdi.13389 ◽

2020 ◽

Author(s):

Linong Ji ◽

Jianhua Ma ◽

Weiping Lu ◽

Jingdong Liu ◽

Jiao’e Zeng ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Phase Iii ◽

Chinese Patients ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Diet And Exercise

Download Full-text

Efficacy and Safety of Linagliptin in Subjects With Long-standing Type 2 Diabetes Mellitus (>10 Years): Evidence From Pooled Data of Randomized, Double-blind, Placebo-controlled, Phase III Trials

Clinical Therapeutics ◽

10.1016/j.clinthera.2014.07.020 ◽

2014 ◽

Vol 36 (11) ◽

pp. 1595-1605 ◽

Cited By ~ 11

Author(s):

Rosemarie Lajara ◽

Richard Aguilar ◽

Uwe Hehnke ◽

Hans-Juergen Woerle ◽

Maximilian von Eynatten

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Pooled Data ◽

Phase Iii Trials

Download Full-text

Efficacy and safety of alogliptin in patients with type 2 diabetes mellitus: A multicentre randomized double-blind placebo-controlled Phase 3 study in mainland China, Taiwan, and Hong Kong

Journal of Diabetes ◽

10.1111/1753-0407.12425 ◽

2016 ◽

Vol 9 (4) ◽

pp. 386-395 ◽

Cited By ~ 10

Author(s):

Changyu Pan ◽

Ping Han ◽

Qiuhe Ji ◽

Chengjiang Li ◽

Juming Lu ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Hong Kong ◽

Mainland China ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text